Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANG siRNA
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal
01
Overview
ANG siRNA is a small interfering RNA (siRNA) designed to silence the expression of the **angiogenin (ANG)** gene. Angiogenin is a member of the RNase A family that plays a critical role in promoting cellular proliferation, migration, and angiogenesis, particularly in several malignancies. In preclinical research involving bladder cancer cell lines (such as KU7 and T24), the use of ANG siRNA has been shown to inhibit tumor cell growth and anchorage-independent growth by mediating the dephosphorylation of ERK1/2 and JNK/SAPK. Furthermore, knocking down ANG expression via siRNA significantly inhibits the migration and invasion of cancer cells and reduces their ability to induce tube formation in endothelial cells, suggesting that ANG is a viable therapeutic target for inhibiting tumor progression and angiogenesis.
- Other names
- angiogenin siRNAsiRNA targeting angiogenin
02
Targets
ANG (Angiogenin (ribonuclease 5))
Beyond the preview
Go deeper on ANG siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANG siRNA.